-
-
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP PATH extension study
-
-
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial
-
-
INTRAVENOUS IMMUNOGLOBULIN (IVIG) FOR RESTABILIZATION TREATMENT AFTER IVIG WITHDRAWAL IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP). RESULTS FROM THE PRE-RANDOMIZATION PHASE OF THE PATH STUDY
-
-
SUBCUTANEOUS IMMUNOGLOBULIN FOR MAINTENANCE TREATMENT IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY - A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL: THE PATH STUDY
-
-
SUBCUTANEOUS IMMUNOGLOBULIN FOR MAINTENANCE TREATMENT IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP), A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL: THE PATH STUDY
-
-
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF TWO DIFFERENT DOSES OF IGPRO20 (SUBCUTANEOUS IMMUNOGLOBULIN) FOR THE TREATMENT OF CIDP: IGG DEPENDENCY AND RESTABILIZATION PHASE
-
-
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial
